Q32 Bio Inc. (QTTB) Non-Current Deffered Revenue (2017 - 2022)

Q32 Bio has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $354000.0 in Q1 2022.

• On a quarterly basis, Non-Current Deffered Revenue fell 90.06% year-over-year to $354000.0 in Q1 2022; TTM through Mar 2022 was $354000.0, a 90.06% decrease from a year earlier, with the FY2021 full-year figure at $1.2 million, down 96.4% from the prior year.
• Non-Current Deffered Revenue was $354000.0 for Q1 2022 at Q32 Bio, down from $1.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $32.1 million in Q4 2020, with the low at $354000.0 in Q1 2022.
• Average Non-Current Deffered Revenue over 5 years is $21.8 million, with a median of $29.8 million recorded in 2020.
• The sharpest annual moves came in 2020 and 2021: Non-Current Deffered Revenue advanced 6.64% in 2020, then plunged 96.4% in 2021.
• Over 5 years, Non-Current Deffered Revenue stood at $30.8 million in 2018, then decreased by 1.98% to $30.1 million in 2019, then rose by 6.64% to $32.1 million in 2020, then slumped by 96.4% to $1.2 million in 2021, then plunged by 69.38% to $354000.0 in 2022.
• The last three Non-Current Deffered Revenue figures came in at $354000.0 (Q1 2022), $1.2 million (Q4 2021), and $2.0 million (Q3 2021), per Business Quant data.